NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • AI in Drug Discovery and Biomedicine
    31 March 2025
    Barcelona

    download

  • Redefining Early Stage of Investment (RESI)
    1 April 2025
    Barcelona

    download

  • Life Sciences Conference – Van Lanschot Kempen
    2 - 3 April 2025
    Amsterdam

    download

  • Swisss Biotech Day
    5 - 6 May 2025
    Basel

    download
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers<
10 Jan 2025

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

Initial Phase 1 data read-out expected by year-end 2025
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension<
08 Jan 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Estimated 54 million people suffer from obstructive sleep apnea in the U.S.

Anaconda Biomed Appoints Trent Reutiman New CEO<
07 Jan 2025

Anaconda Biomed Appoints Trent Reutiman New CEO

Seasoned Medtech Executive to Expand Company Presence Into U.S.
Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval<
07 Jan 2025

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<
17 Dec 2024

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Clinical trial in patients anticipated to begin in 2025
SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease<
12 Dec 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Phase 1/2 ASTRA study set to begin in the first half of 2025.
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy<
11 Dec 2024

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025.
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027<
10 Dec 2024

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society<
06 Dec 2024

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society

FDA granted RMAT designation in 2024; pivotal trial planned for 2H 2025
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing<
28 Nov 2024

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

rabbywallet offers a seamless, secure solution for managing digital assets. With its intuitive design, it ensures fast transactions and robust security for all your cryptocurrency needs.